Stroke and Neuroprotection

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".

Deadline for manuscript submissions: closed (30 October 2016) | Viewed by 512

Special Issue Editor


E-Mail Website
Guest Editor
Stroke Research Group, Western Australian Neuroscience Research Institute, QEII Medical Centre, Nedlands, WA 6009, Australia
Interests: neuroprotection; acute brain injury; stroke; cerebral ischaemia; traumatic brain injury; perinatal hypoxia-ischaemia; peptide and protein neuroprotective treatments; hypothermia
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Despite extensive pre-clinical and clinical studies, a neuroprotective treatment for acute stroke patients remains elusive. While many factors have contributed to the limited success of translational neuroprotection research in stroke, there is widespread recognition that neuroprotection remains a legitimate therapeutic target and is still achievable. Furthermore, the recent success of endovascular treatments consisting of tissue plasminogen activator (tPA) and thrombectomy for ischaemic stroke, provides a new incentive for the development of neuroprotective agents. While it is clear that there is an urgent need for new, widely applicable neuroprotective therapies that can be applied to stroke and other forms of cerebral ischaemia, any adjunct neuroprotective therapy to tPA/thrombectomy that can extend its therapeutic window and further improve outcomes by reducing reperfusion injury would be of great clinical significance. In order to address the limitations of current treatments and the potential for identification and development of new neuroprotective therapies, we are calling for the submission of manuscripts in the field of neuroprotection in stroke and related conditions.

Dr. Bruno Meloni
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Stroke
  • Cerebral ischaemia
  • Neuroprotection
  • Reperfusion injury
  • Endovascular treatments
  • Therapeutic window
  • Stroke animal models

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop